| [ Summary ] |
All‒oral combinations of direct‒acting antivirals may improve the efficacy and safety outcomes for patients with hepatitis C virus (HCV) infection. In a phase 3 study, patients with chronic HCV genotype 1b infection were enrolled in 24 centers in Japan. The patients received 60 mg of Daclatasvir (DCV) once daily, and 100 mg of Asunaprevir (ASV) twice daily for 24 weeks. A Sustained Virologic Response 24 weeks after treatment (SVR24) was achieved in 81‒91 % of all patients. Moreover, SVR24 was achieved in 94‒100 % of the patients who were not infected with NS3 and NS5A RAVs. A real life cohort study in the Toranomon Hospital showed that with DCV+ASV combination therapy, SVR12 was achieved in 88 % of all patients and in 95 % of patients not infected with NS3 and NS5A RAVs. In conclusion, interferon‒free, ribavirin‒free all‒oral therapy with the DCV+ASV combination for 24 weeks is well tolerated and can be used to achieve a high rate of SVR in patients not infected with NS3 and NS5A RAVs. |